Major Growth Driver Identified in 2025 Ribose-Nucleic Acid (RNA)-Based Therapeutics Market: Increasing Prevalence Of Cancer On The RNA-Based Therapeutics Market

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for therapeutics based on ribose-nucleic acid (RNA) has witnessed significant expansion in the past few years. The market, which stands at $15.79 billion in 2024, is set to grow to $17.26 billion by 2025 with a compound annual growth rate (CAGR) of 9.3%. Factors driving this historic growth include increased investments and funding, the discovery of RNA interference (RNAi), clinical triumphs with antisense oligonucleotides (ASOs), supportive regulatory structures, and alliances and partnerships.

Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Size Forecast: What's the Projected Valuation by 2029?
Over the coming years, the market for ribose-nucleic acid (RNA)-based therapeutics is projected to experience robust growth. It is expected to expand to $24.26 billion by 2029, with a compound annual growth rate (CAGR) of 8.9%. Various factors contribute to this predicted market growth during the forecast period, such as expanding indications, growing market demand and adoption, regulatory support, the influx of AI and machine learning, and their emergent utilisation in rare diseases. Upcoming trends for this period include the development of superior delivery systems, RNA therapeutics aimed at multiple targets, personalised RNA therapies, advancements in regulation, and commercialisation which are fostering market growth.

View the full report here:
https://www.thebusinessresearchcompany.com/report/ribose-nucleic-acid-rna-based-therapeutics-global-market-report

What Are the Drivers Transforming the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market?
The rising occurrence of cancer is anticipated to spur the evolution of the ribose-nucleic acid (RNA)-based therapeutics market in the future. Cancer is a disease where irregular cells proliferate and disperse unchecked, which could potentially result in death if not treated. This growing incidence of cancer is attributable to an aging demographic, alterations in lifestyle, increased exposure to hazards, and advancements in detection techniques. RNA-based therapeutics present a significant potential for treating cancer by directly addressing the cancer's genetic and molecular processes. For example, in August 2023, around 151,000 people were diagnosed with cancer, (excluding basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) of the skin) in 2021, as per data from the Australian Institute of Health and Welfare, a health-focused government agency in Australia. This figure is anticipated to rise to 185,000 by 2030. Consequently, the escalating incidence of cancer is fuelling the growth of the ribose-nucleic acid (RNA)-based therapeutics market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18454&type=smp

What Long-Term Trends Will Define the Future of the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market?
Leading firms in the ribose nucleic acid (RNA)-based therapeutics market are putting their efforts into the creation of groundbreaking medical solutions like messenger RNA (mRNA)-based booster vaccines, with the aim of boosting immunization efficiency, tackling new viral strains, and augmenting the overall longevity of vaccine-induced immunity. The mechanism of an mRNA-based booster vaccine involves using messenger RNA to instigate cells to produce a protein that intensifies the body's immune defense against a specific pathogen. For example, Gennova Biopharmaceuticals Ltd., an India-based pharmaceutical firm, in June 2023, rolled out GEMCOVAC-OM, the first mRNA booster vaccine developed in India specifically for combating the Omicron variant of COVID-19. This booster becomes crucial due to the restricted effectiveness of the initial vaccines against Omicron. Leaning on mRNA technology, GEMCOVAC-OM bolsters immunity and provides superior protection against the mutating virus.

Which Segments in the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Offer the Most Profit Potential?
The ribose-nucleic acid (RNA)-based therapeutics market covered in this report is segmented -

1) By Type: RNA Interference (RNAi), RNA Antisense
2) By Technology: Enabling Technology, Enabled Technology
3) By Therapeutic Area: Oncology, Genetic Disorder, Ophthalmology, Hematological Disorders, Acute Hepatic Porphyria (AHP), Other Therapeutic Areas
4) By End User: Research Institutes, Hospitals And Clinics

Subsegments:
1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), MicroRNA (miRNA)
2) By RNA Antisense: Antisense Oligonucleotides (ASOs), Antisense RNA

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=18454&type=smp

Which Firms Dominate the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market by Market Share and Revenue in 2025?
Major companies operating in the ribose-nucleic acid (RNA)-based therapeutics market are F. Hoffmann-La Roche AG, Eli Lilly and Company, Novo Nordisk A/S, Regeneron Pharmaceuticals, Biogen Inc., Houston Methodist Hospital, BioNTech, University of Oxford, Alnylam Pharmaceuticals, Sarepta Therapeutics, Flagship Pioneering, Ionis Pharmaceuticals, Akcea Therapeutics Inc, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Wave Life Sciences, Pharmaceutical Technology, Quark Pharmaceuticals, Tekmira Pharmaceuticals, ReCode Therapeutics, Arbutus Biopharma Corporation, Benitec Biopharma Inc., Olix Pharmaceuticals, Alltrna Inc., Orbital Therapeutics

Which Regions Offer the Highest Growth Potential in the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market?
North America was the largest region in the ribose-nucleic acid (RNA)-based therapeutics market in 2024. The regions covered in the ribose-nucleic acid (RNA)-based therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18454

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.